Proquest Dissertations

Total Page:16

File Type:pdf, Size:1020Kb

Proquest Dissertations Aqueous solubility prediction of organic compounds Item Type text; Dissertation-Reproduction (electronic) Authors Yang, Gang Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 01/10/2021 15:23:34 Link to Item http://hdl.handle.net/10150/298795 AQUEOUS SOLUBILITY PREDICTION OF ORGANIC COMPOUNDS by Gang Yang A Dissertation Submitted to the Faculty of the DEPARTMENT OF PHARMACEUTICAL SCIENCES In Partial Fulfillment of the Requirements For the Degree of DOCTOR OF PHILOSOPHY In the Graduate College THE UNIVERSITY OF ARIZONA 2005 UMI Number: 3158221 INFORMATION TO USERS The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleed-through, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. UMI UMI Microform 3158221 Copyright 2005 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, Ml 48106-1346 2 The University of Arizona ® Graduate College As members of the Final Examination Committee, we certify that we have read the dissertation prepared by Gang Yang entitled Aqueous Solubility Prediction of Organic Compounds and recommend that it be acceptable as fulfilling the dissertation requirement for the Degree of Doctor of Philosophv Samuel HTy alkowsky, Ph.D. date /'QC Michael Mayersohn, Prf®. date Paul B. Myrdal, Ph.Dr^ date date date Final approval and acceptance of this dissertation is contigent upon the candidate's submission of the final copies of the dissertation to the Graduate College. I hereby certify that I have read this dissertation prepared under my direction and recommend that it be accepted as fi^filling the disseration requirement. Dissertation DirectorfSamuel H. Yalkowsky, Ph.D. date 3 STATEMENT BY AUTHOR This dissertation has been submitted in partial fulfillment of requirements for an advanced degree at The University of Arizona and is deposited in the University Library to be made available to borrowers under rules of the Library. Brief quotations from this dissertation are allowable without special permission, provided that accurate acknowledgment of source is made. Requests for permission for extended quotation from or reproduction of this manuscript in whole or in part may be granted by the head of the major department or the Dean of the Graduate College when in his or her judgment the proposed use of the material is in the interests of scholarship. In all other instances, however, permission must be obtained from the author. SIGNED: 4 ACKNOWLEDGEMENTS I would like to express my sincere gratitude to my advisor, Dr. Samuel Yalkowsky, for giving me the opportunity and financial support to study in the field of Pharmaceutical Sciences, for his expert guidance and mentorship, and for his constant support and encouragement over the years at Arizona. He has made it a challenging and fun experience that I will cherish for years to come. I would like to thank members of my major committee. Dr. Michael Mayersohn and Dr. Paul Myrdal, for reviewing drafts of the dissertation on a very short notice and providing helpful comments on the dissertation. My appreciations also go to the members of my minor committee. Dr. Srini Raghavan and Dr. Scott Saavedra, for dedicating their time to serve on my committee. During the years at Arizona, I had the pleasure to work with many friends and colleagues including Neera, Jeff, Debra, Yingqing, Tapan, Ahbi, Yan, Jenny, Akash, Kia, Stephen, Ritesh, Yvonne, Huadong, Abhi, Kelly, Phil, Julie, Eric and Will. I would like to thank all of them for being there for me when I needed help. My special thanks go to Dr. Wolf-Dietrich Dilenfeldt for his fragmentation program. I am greatly indebted to many teachers back in China, in particularly, Xinfang Liu and Manguo Tao for keeping me interested in science and helping me excel. At last, I would like to thank my family: my fiancee Hui for her love and encouragement throughout my study; my parents and sister for their years of loving support and understanding. 5 DEDICATION To my parents and Hui 6 TABLE OF CONTENTS LIST OF FIGURES 10 LIST OF TABLES 11 ABSTRACT 12 CHAPTER 1: INTRODUCTION 14 CHAPTER 2: AQUEOUS SOLUBILITY PREDICTION METHODS 21 INTRODUCTION 21 THE IDEAL SOLUTION AND REGULAR SOLUTION THEORY 21 Ideal Solution 21 Regular Solution 22 Aqueous Solution 22 Crystalline Solute 23 REVIEW OF LITERATURE 24 Group Contribution Approach 24 Mobile Order Theory 25 Linear Solvation Energy Relationship (LSER) 26 Atom Type Electrotopological State Indices 27 MODEL DEVELOPMENT 28 General Solubility Equation 28 The AQUAFAC Method 29 A New Model 30 CHAPTER 3: DATA COLLECTION AND ANALYSIS 32 INTRODUCTION 32 DATA 33 Solubility Data 33 Melting Point (MP) 36 Octanol-Water Partition Coefficient (P) 36 RELATIONSHIPS 40 7 TABLE OF CONTENTS - Continued Regression Analysis 40 CLOGP Prediction Evaluation 41 Predicted versus Experimental Octanol-Water Partition Coefficient 42 Solubility and Octanol-Water Partition Coefficient 44 Solubility and Melting Point 50 CHAPTER 4: STRUCTURAL FRAGMENTATION 52 INTRODUCTION 52 SMILES 54 SMARTS 57 STRUCTURAL FRAGMENTATION PROGRAM 57 FRAGMENTATION SCHEME 59 CHAPTER 5: EVALUATION OF SOLUBILITY PREDICTION BY THE GENERAL SOLUBILITY EQUATION ON A SET OF DIVERSE COMPOUNDS 64 INTRODUCTION 64 METHODS 65 Data Set 65 Evaluation 66 Regression Analysis 68 RESULTS AND DISCUSSION 69 Overall Performance 69 Solid Versus Liquid 76 Non-electrolyte Versus Weak Electrolyte 78 Regression Analysis 82 SUMMARY 83 CHAPTER 6: COMPARISON OF THE GENERAL SOLUBILITY EQUATION AND THE METHOD USING AN AMENDED SOLVATION ENERGY RELATIONSHIP. 84 INTRODUCTION 84 METHODS 86 8 TABLE OF CONTENTS - Continued RESULTS 87 Octanol-Water Partition Coefficients 87 Melting Point 89 Solubility 90 DISCUSSION 93 SUMMARY 98 CHAPTER 7: DEVELOPMENT OF THE EXTENDED AQUAFAC MODEL 99 INTRODUCTION 99 METHODS 101 Data Set 101 Aqueous Activity Coefficient 101 Structural Fragmentation 102 Regression Analysis 102 RESULTS 103 Fragmentation Performance 103 Regression Analysis 103 Group Contribution Values qi 103 Aqueous Solubility Prediction 107 CHAPTER 8: DEVELOPMENT OF A NEW GROUP CONTRIBUTION MODEL FOR AQUEOUS SOLUBILITY PREDICTION 108 INTRODUCTION 108 METHODS 110 Data Set 110 Structural Fragmentation 110 Regression Analysis 110 RESULTS Ill Fragmentation Performance Ill Regression Analysis Ill 9 TABLE OF CONTENTS - Continued Group Contribution Values mi 112 CHAPTER 9: COMPARISON OF AQUEOUS SOLUBILITY PREDICTION MODELS 116 PREDICTION COMPARISON 117 SUMMARY 121 APPENDIX A. Experimental Solubility Collection with Melting Point, log P and Predicted Solubility Using the General Solubility Equation 122 APPENDIX B. Comparison of Predicted Solubility Using the General Solubility Equation and the Amended Solvation Energy Relationship 161 APPENDIX C. Predicted Solubility for Test Set 1 175 APPENDIX D. Predicted Solubility for Test Set 2 176 APPENDIX E. Predicted Solubility for Test Set 3 177 REFERENCES 179 10 LIST OF FIGURES Figure 3.1: Log solubility (log Sw) distribution of 1804 compounds in the data set 35 Figure 3.2: Melting point (MP) distribution of 1037 solids in the data set 37 Figure 3.3: Calculated log octanol-water partition coefficient (Clog?) distribution of 1804 compounds in the data set 38 Figure 3.4: Experimental log octanol-water partition coefficient (MlogP) distribution of 1226 compounds in the data set 39 Figure 3.5: Plot of calculated log octanol-water partition coefficients (ClogP) versus experimental log octanol-water partition coefficients (MlogP) 43 Figure 3.6: Scatterplot of log versus calculated log octanol-water partition coefficients (ClogP) for 597 liquids or gases in the data set 46 Figure 3.7: Scatterplot of log Sw versus experimental log octanol-water partition coefficients (MlogP) for 393 liquids or gases with available experimental log P in the data set 47 Figure 3.8: Scatterplot of log aqueous solubilities (log Sw) versus calculated log octanol-water partition coefficients (ClogP) for all 1804 compounds in the data set 48 Figure 3.9: Scatterplot of log aqueous solubilities (log Sw) versus experimental log octanol-water partition coefficients (MlogP) for 1225 compounds with available experimental log P in the data set 49 Figure 3.10: Scatterplot of log Sw versus experimental melting point for 1525 compounds with available melting point information in the data set 51 Figure 4.1: An example illustrating the expression of Benzocaine structure in SMILES 56 Figure 4.2: Fragmentation of benzocaine structure according to the AQUAFAC Scheme 63 Figure 5.1: Plot of predicted log Sw versus experimental log Sw 71 Figure 5.2: Absolute prediction error distribution 72 Figure 5.3: Plot of prediction error against experimental log Sw 73 Figure 5.4: Plot of prediction error against calculated log P (ClogP) 74 Figure 5.5: Plot
Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • Factors Influencing Pesticide Resistance in Psylla Pyricola Foerster and Susceptibility Inits Mirid
    AN ABSTRACT OF THE THESIS OF: Hugo E. van de Baan for the degree ofDoctor of Philosopbv in Entomology presented on September 29, 181. Title: Factors Influencing Pesticide Resistance in Psylla pyricola Foerster and Susceptibility inits Mirid Predator, Deraeocoris brevis Knight. Redacted for Privacy Abstract approved: Factors influencing pesticide susceptibility and resistance were studied in Psylla pyricola Foerster, and its mirid predator, Deraeocoris brevis Knight in the Rogue River Valley, Oregon. Factors studied were at the biochemical, life history, and population ecology levels. Studies on detoxification enzymes showed that glutathione S-transferase and cytochrome P-450 monooxygenase activities were ca. 1.6-fold higherin susceptible R. brevis than in susceptible pear psylla, however, esterase activity was ca. 5-fold lower. Esterase activity was ca. 18-fold higher in resistant pear psylla than in susceptible D. brevis, however, glutathione S-transferase and cytochrome P-450 monooxygenase activities were similar. Esterases seem to be a major factor conferring insecticideresistance in P. Pvricola. Although the detoxification capacities of P. rivricola and D. brevis were quite similar, pear psylla has developed resistance to many insecticides in the Rogue River Valley, whereas D. brevis has remained susceptible. Biochemical factors may be important in determining the potential of resistance development, however, they are less important in determining the rate at which resistance develops. Computer simulation studies showed that life history and ecological factors are probably of greater importancein determining the rate at which resistance develops in P. pvricola and D. brevis. High fecundity and low immigration of susceptible individuals into selected populations appear to be major factors contributing to rapid resistance development in pear psylla compared with D.
    [Show full text]
  • Replacement Therapy, Not Recreational Tonic Testosterone, Widely Used As a Lifestyle Drug, Is a Medicine and Should Be Kept As Such
    correspondence Replacement therapy, not recreational tonic Testosterone, widely used as a lifestyle drug, is a medicine and should be kept as such. Sir — We read with great interest the News male tonics and remedies — most harmless, your Feature that there is a need for large- Feature “A dangerous elixir?” (Nature 431, but some as drastic as grafting goat testicles scale, long-term clinical trials to address 500–501; 2004) reporting the zeal with onto humans. Unfortunately, a certain several issues associated with testosterone which testosterone is being requested by amount of quackery is now perceived to be use. For example, testosterone therapy may men who apparently view the hormone as associated with testosterone therapy, and the be beneficial against osteoporosis, heart a ‘natural’ alternative to the drug Viagra. increased prescription of the hormone in disease and Alzheimer’s disease, but the Like Viagra, testosterone replacement recent years does little to dispel this notion. dangers remain obscure. therapy — with emphasis on the word Nonetheless, as your Feature highlights, Until we know more, both prescribing ‘replacement’ — is a solution to a very real hypogonadism is a very real clinical clinicians and the male population need to clinical problem. There is a distinction condition. It is characterized by abnormally be aware that testosterone, like any other between patients whose testosterone has low serum levels of testosterone, in medication, should only be administered declined to abnormally low levels, and conjunction with symptoms such as to patients for whom such therapy is individuals seeking testosterone as a pick- mood disturbance, depression, sexual clinically indicated. me-up.
    [Show full text]
  • Occurrence, Elimination, and Risk of Anticoagulant Rodenticides in Wastewater and Sludge
    Occurrence, elimination, and risk of anticoagulant rodenticides in wastewater and sludge Silvia Lacorte, Cristian Gómez- Canela Department of Environmental Chemistry, IDAEA-CSIC, Jordi Girona 18-26, 08034 Barcelona Rats and super-rats Neverending story 1967 Coumachlor 1 tn rodenticides /city per campaign “It will be the LAST ONE” Rodenticides Biocides: use regulated according to EU. Used mainly as bait formulations. First generation: multiple feedings, less persistent in tissues, commensal and outdoor use. Second generation: single feeding (more toxic), more persistent in tissue, commensal use only. Toxic: vitamin K antagonists that cause mortality by blocking an animal’s ability to produce several key blood clotting factors. High oral, dermal and inhalation toxicity. Origin and fate of rodenticides Study site: Catalonia (7.5 M inhabitants) 1693 km of sewage corridor 13 fluvial tanks (70.000 m3) 130,000,000 € / 8 YEARS 32,000 km2 378,742 kg/y AI 2,077,000 € Objectives 1. To develop an analytical method to determine most widely used rodenticides in wastewater and sludge. 2. To monitor the presence of rodenticides within 9 WWTP receiving urban and agricultural waters. 3. To evaluate the risk of rodenticides using Daphnia magna as aquatic toxicological model. 4. To study the accumulation of rodenticides in sludge. Compounds studied Coumachlor* Pindone C19H15ClO4 C14H14O3 Dicoumarol Warfarin C19H12O6 C19H16O4 Coumatetralyl Ferulenol FGARs C19H16O3 C24H30O3 Acenocoumarol Chlorophacinone • Solubility C19H15NO6 C23H15ClO3 0.001-128 mg/L • pKa 3.4-6.6 Flocoumafen Bromadiolone C H F O C H BrO 33 25 3 40 30 23 4 • Log P 1.92-8.5 Brodifacoum Fluindione C H BrO 31 23 3 C15H9FO2 SGARs Difenacoum Fenindione C31H24O3 C15H10O2 1.
    [Show full text]
  • Wastewater-Borne Exposure of Limnic Fish to Anticoagulant Rodenticides
    Water Research 167 (2019) 115090 Contents lists available at ScienceDirect Water Research journal homepage: www.elsevier.com/locate/watres Wastewater-borne exposure of limnic fish to anticoagulant rodenticides * Julia Regnery a, , Pia Parrhysius a, Robert S. Schulz a, Christel Mohlenkamp€ a, Georgia Buchmeier b, Georg Reifferscheid a, Marvin Brinke a a Department of Biochemistry, Ecotoxicology, Federal Institute of Hydrology, Am Mainzer Tor 1, 56068 Koblenz, Germany b Unit Aquatic Ecotoxicology, Microbial Ecology, Bavarian Environment Agency, Demollstr. 31, 82407 Wielenbach, Germany article info abstract Article history: The recent emergence of second-generation anticoagulant rodenticides (AR) in the aquatic environment Received 18 June 2019 emphasizes the relevance and impact of aquatic exposure pathways during rodent control. Pest control Received in revised form in municipal sewer systems of urban and suburban areas is thought to be an important emission 12 September 2019 pathway for AR to reach wastewater and municipal wastewater treatment plants (WWTP), respectively. Accepted 13 September 2019 To circumstantiate that AR will enter streams via effluent discharges and bioaccumulate in aquatic or- Available online 14 September 2019 ganisms despite very low predicted environmental emissions, we conducted a retrospective biological monitoring of fish tissue samples from different WWTP fish monitoring ponds exclusively fed by Keywords: fl Bioaccumulation municipal ef uents in Bavaria, Germany. At the same time, information about rodent control in asso- Biocides ciated sewer systems was collected by telephone survey to assess relationships between sewer baiting Monitoring and rodenticide residues in fish. In addition, mussel and fish tissue samples from several Bavarian surface PBT-Substances waters with different effluent impact were analyzed to evaluate the prevalence of anticoagulants in Sewer baiting indigenous aquatic organisms.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • DDT and Its Derivatives Have Remained in the Environment
    International Journal of Molecular Sciences Review A Novel Action of Endocrine-Disrupting Chemicals on Wildlife; DDT and Its Derivatives Have Remained in the Environment Ayami Matsushima Laboratory of Structure-Function Biochemistry, Department of Chemistry, Faculty of Science, Kyushu University, Fukuoka 819-0395, Japan; [email protected]; Tel.: +81-92-802-4159 Received: 20 March 2018; Accepted: 2 May 2018; Published: 5 May 2018 Abstract: Huge numbers of chemicals are released uncontrolled into the environment and some of these chemicals induce unwanted biological effects, both on wildlife and humans. One class of these chemicals are endocrine-disrupting chemicals (EDCs), which are released even though EDCs can affect not only the functions of steroid hormones but also of various signaling molecules, including any ligand-mediated signal transduction pathways. Dichlorodiphenyltrichloroethane (DDT), a pesticide that is already banned, is one of the best-publicized EDCs and its metabolites have been considered to cause adverse effects on wildlife, even though the exact molecular mechanisms of the abnormalities it causes still remain obscure. Recently, an industrial raw material, bisphenol A (BPA), has attracted worldwide attention as an EDC because it induces developmental abnormalities even at low-dose exposures. DDT and BPA derivatives have structural similarities in their chemical features. In this short review, unclear points on the molecular mechanisms of adverse effects of DDT found on alligators are summarized from data in the literature, and recent experimental and molecular research on BPA derivatives is investigated to introduce novel perspectives on BPA derivatives. Especially, a recently developed BPA derivative, bisphenol C (BPC), is structurally similar to a DDT derivative called dichlorodiphenyldichloroethylene (DDE).
    [Show full text]
  • Synthesis of Condensed 1,2,4-Triazolo-Heterocycles
    Chemistry SYNTHESIS OF CONDENSED 1,2,4-TRIAZOLO-HETEROCYCLES MOHAMMED A. E. SHABAN ADEL Z. NASR MAMDOUH A. M. TAHA SUMMARY: Cyclization of 2-hydrazino-1, 3-benzothiazole, 2-hydrozinoquioline, 2-hydrazinolepidine, and 2-hydrazino-pyridine with one-carbon cyclizing agents such as triethyl orthoformate, ethyl chlorofor- mate, urea, phenylthiourea, and carbon disulfide gave 3-substituted-1,2,4-triazolo (3,4, -b) 1, 3-benzothia- zoles, 3-substituted-1,2,4-triazolo (4,3-a) quinolines, 3-substituted-1,2,4-triazolo (4,3-a) quinolines, 3-substituted-1,2,4-triazolo (4,3-a) lepidines and 3-substituted-1,2,4-triazolo (4,3-a) pyridines respectively. Reactions with acetic acid and acetic anhydride gave the corresponding acetyl hydrazines which were cyclized to the 3-methyl 1,2,4-triazolo-heterocyles. Ring closure with phenyl isocyanate and phenyl isothio- cyanate, gave the intermediate 4-phenylsemicarbazides and 4-phenylthiosemicarbazides which, upon fusion, afforded the corresponding 3-oxo- and 3-thioxo-1,2,4-triazolo-heterocyles. The 3-oxo-compounds were also obtained when 2-chloroquinoloni or 2-chlorolepidine was fused with semicarbazide hydrochloride. Key Words: Synthesis, amidrazones, triazolo-heterocycles. INTRODUCTION The synthesis and biological activities of condensed In an attempt to prepare 3-methyl-1,2,4-triazolo (3,4-b) 1,2,4-triazolo (3,4-z) heterocyles have recently been 1,3-benzothiazole (5a) by heating 2-hydrazino-1, 3- reviewed (14). Several condendes 1,2,4-triazolo-hetero- benzothiazole (1a) with an excess of acetic acid or acetic cyles exhibit various biological activities such as fungicidal anhydride, 1,1,2-triacetyl-2-(1,3-benzothiazol-2-yl) hyd- (1,9) bactericidal (1,9) analgesic (4,7,10) anxiolytic (8) razine (3a) was obtained.
    [Show full text]
  • Synthesis of [1,3,2]Dithiazolo[4,5-B][1,2,5]Oxadiazolo[3,4-E]Pyrazines
    General Papers ARKIVOC 2011 (xi) 69-81 Synthesis of [1,3,2]dithiazolo[4,5-b][1,2,5]oxadiazolo[3,4-e]pyrazines Lidia S. Konstantinova,a Vadim V. Popov,a Natalia V. Obruchnikova,a Konstantin A. Lyssenko,b Ivan V. Ananyev,b and Oleg A. Rakitina* aN. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Leninsky Prospect, 47, 119991 Moscow, Russia bA. N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, Vavilov Str., 28, 119991 Moscow, Russia E-mail: [email protected] Abstract The reaction temperature has a strong impact on the results of chlorination of 5,6-bis(tert- butylthio)[1,2,5]oxadiazolo[3,4-b]pyrazine that is readily prepared from 5,6- dichloro[1,2,5]oxadiazolo[3,4-b]pyrazine and sodium tert-butylsulfide. Mono- and bis(sulfenylchlorides) were selectively obtained in high yield and their structure was confirmed by the reaction with morpholine. Treatment of [1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-disulfenyl dichloride with primary aliphatic amines and benzylamine afforded N-substituted [1,3,2]dithiazolo[4,5-b][1,2,5]oxadiazolo[3,4-e]pyrazines in moderate yields. Novel pentacyclic [1,2,5]oxadiazolo[3'',4'':5',6']pyrazino[2',3':5,6][1,2,4]thiadiazino[3,4-b][1,3]benzothiazole, whose structure was confirmed by X-ray diffraction, was obtained by the reaction of this disulfenyl dichloride with 2-aminobenzothiazole. Keywords: Fused 1,3,2-dithiazoles, [1,2,5]oxadiazolo[3,4-b]pyrazines, disulfenyl dichlorides, primary amines, bis(tert-butylthio) derivatives, chlorination Introduction Amongst five-membered
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Annex XV Report
    Annex XV report PROPOSAL FOR IDENTIFICATION OF A SUBSTANCE OF VERY HIGH CONCERN ON THE BASIS OF THE CRITERIA SET OUT IN REACH ARTICLE 57 Substance Name(s): 1,6,7,8,9,14,15,16,17,17,18,18- Dodecachloropentacyclo[12.2.1.16,9.02,13.05,10]octadeca-7,15-diene (“Dechlorane Plus”TM) [covering any of its individual anti- and syn-isomers or any combination thereof] EC Number(s): 236-948-9; -; - CAS Number(s): 13560-89-9; 135821-74-8; 135821-03-3 Submitted by: United Kingdom Date: 29 August 2017 ANNEX XV – IDENTIFICATION OF DECHLORANE PLUS AS SVHC CONTENTS PROPOSAL FOR IDENTIFICATION OF A SUBSTANCE OF VERY HIGH CONCERN ON THE BASIS OF THE CRITERIA SET OUT IN REACH ARTICLE 57..........................................................................................IV PART I ...............................................................................................................................................1 JUSTIFICATION ..................................................................................................................................1 1. IDENTITY OF THE SUBSTANCE AND PHYSICAL AND CHEMICAL PROPERTIES ...................................2 1.1 Name and other identifiers of the substance................................................................................2 1.2 Composition of the substance ........................................................................................................2 1.3 Identity and composition of degradation products/metabolites relevant for the SVHC assessment ....................................................................................................................................3
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]